Kadimastem - Stem Cell to Cure Diseases

News & Events > Press Releases

Kadimastem was honored with a prize for excellence for the presentation of the company's technology at the European conference of ALS at Oxford University

Jun. 27, 2018

Between June 20 and 22, 2018, European conference was held for ALS (ENCALS) at Oxford University in England. During the conference, the company presented its scientific work on ALS cell therapy. The work presented describes the comprehensive scientific research led by Prof. Michel Revel, Chief Scientist of the company, and Dr. Michal Izrael, VP of R&D in the field of neurodegenerative diseases in the company, on the company's flagship product, AstroRx®. The work presented at the conference by Dr. Guy Slutsky, was awarded a prize for excellence among the hundreds of research papers presented at the conference (http://www.www.encals.eu). The work describes the safety and efficacy results of the product in model animals and its various mechanisms of action, which prevent the death of motor neurons that are damaged in ALS. The results described in the article constitute the foundation of the clinical trial the company is currently conducting in ALS patients using AstroRx®. The clinical trial is being conducted in the Department of Neurology of the Hadassah Ein-Kerem Medical Center, and interim results are expected during the coming year.

Professor Michel Revel, the company's Chief Scientist, noted: "Winning the award for excellence in an international conference that deals with treatments for severe neurological disease (ALS) is testimony to the recognition of a breakthrough by Kadimastem and proves the scientific community's assessment of the company's product development."

Yossi Ben Yossef' the company's CEO, stated: "I am pleased and happy with the decision of the scientific committee of the conference and see this as an vote of confidence and recognition by the scientific community of the importance of the company's technology for the treatment of ALS.”

 

About Kadimastem

Kadimastem (www.kadimastem.com) is a clinical stage biotechnology company that develops industrial regenerative medicine therapies based on differentiated cells derived from Human Embryonic Stem Cells (hESCs) to treat neuro-degenerative diseases such as ALS, as well as Diabetes. The company was founded in August 2009 by Professor Michel Revel and Yossi Ben Yosef, and is traded on the Tel Aviv Stock Exchange (TASE: KDST). The company's chairman is Dr. Eli Opper, formerly the Chief Scientist of the Israeli Ministry of Industry, Labor and Trade. The company's investors, in addition to the founders, include Altshuler Shaham Investment House, foreign investors (Julien Ruggieri and Avi Meizler), and additional institutional investors.

Kadimastem was founded based on patent protected technology that was developed at the Weizmann Institute of Science. Based on the Company's unique platform, Kadimastem is developing technology for regenerative medicine, which repairs and replaces organs and tissue by using functioning cells differentiated from stem cells. The Company focuses on transplanting healthy brain cells to support the survivability of nerve cells as cell therapy for ALS, and transplanting insulin-secreting pancreatic cells for the treatment of insulin-dependent diabetes.

Kadimastem has an extensive scientific advisory board, featuring prominent scientists and pioneers: in the embryonic stem cells field, Professor Benjamin Reubinoff, Director of the Hadassah Human Embryonic Stem Cell Research Center and Senior Physician at the Department of Obstetrics and Gynecology at the Hadassah University Medical Center; Professor Joseph Itskovich, world renowned expert and pioneer in pluripotent stem cell research and former head of Obstetrics and Gynecology at RAMBAM Medical Center; in the neurodegenerative disease field, Professor Tamir Ben-Hur, Head of the Department of Obstetrics and Gynecology at Hadassah University Medical Center; and in the diabetes field, Professor Shimon Efrat, professor of Human Molecular Genetics and Juvenile Diabetes at Tel Aviv University and a world renowned expert in cell replacement therapy for diabetes and Professor Eddy Karnieli, former Director of the Institute for Endocrinology, Diabetes and Metabolism at the RAMBAM Medical Center, and a world renowned expert in these fields.


Press Releases Archive